key: cord-0799242-i0brx1v3 authors: Cobo, Fernando; Pérez-Carrasco, Virginia; García-Salcedo, José A.; Navarro-Marí, José María title: BACTEREMIA caused by VEILLONELLA DISPAR in an oncological patient date: 2020-10-16 journal: Anaerobe DOI: 10.1016/j.anaerobe.2020.102285 sha: da125e696b3f04900761bb162bc51575fadf6d2f doc_id: 799242 cord_uid: i0brx1v3 Veillonella dispar is a Gram-negative anaerobic coccus involved in only a few human diseases. We report the second case of bacteremia due to this microorganism in an elderly patient. A 72-year-old man with a history of bladder cancer presented with diarrhea, vomiting, and fever for 48 hours. After the diagnosis of septic shock, four sets of blood cultures were taken, and three of them yielded V. dispar. Resistance to metronidazole, penicillin, and piperacillin-tazobactam was documented. Treatment with clindamycin was started, and the patient was discharged after improvement in his general condition. gastrointestinal tract and is also found in the urogenital area [2] [3] [4] . Among the different 52 species of this genus, V. parvula has been the most frequently isolated. Identification of 53 members of this genus at species level is hampered by the lack of discriminating 54 phenotypic tests. We recently observed a rare case of bacteremia in pure culture in a 55 patient with a clinical history of cancer. To our best knowledge, this is the second 56 description of V. dispar obtained from blood culture. 57 58 A 72-year-old man was admitted to the Emergency Department of our hospital after 48 60 hours with diarrhea, vomiting, and fever (38.5ºC). His clinical history was remarkable 61 for chronic renal disease and a bladder cancer treated 8 years earlier by bladder 62 transurethral resection and hormone therapy. At admission no active disease was found. 63 The physical exam showed a febrile patient (38.5 ºC) with tachypnea (25 bpm), and a 64 (3000 cc of crystalloids), and his blood lactate level at that time was 5 meQ/L. He was 73 then admitted to the ICU due to septic shock requiring treatment with vasoactive drugs. 74 The result of a polymerase chain reaction test for SARS-Coronavirus 2 was negative. 75 In the microbiology laboratory, samples were inoculated onto the BACTEC FX 40 76 (Becton Dickinson, Franklin Lakes, NY) monitorization system for culture. On day 2 of 77 incubation, the two anaerobic bottles from two blood culture sets were positive. The 78 samples were subcultured on aerobic or anaerobic blood agar (BD Columbia Agar with 79 5% Sheep Blood, Becton Dickinson, Franklin Lakes, NY). All media were incubated at 80 was not consistent, because there was also a matching pattern with V. parvula and V. 87 Most in vitro studies suggest that Veillonella spp. remain susceptible to a wide range of 133 commonly used drugs. Among case reports, several did not perform antimicrobial 134 susceptibility testing [8, 10, 15] and three found that Veillonella isolates were 135 susceptible to all antimicrobials tested, although there was a high heterogeneity [11, 13, 136 14] . High resistance to metronidazole (MIC > 128 mg/L) was described in one report 137 [9] and resistance to penicillin and metronidazole in another 12], whereas metronidazole 138 was found to be active against 100% of Veillonella isolates in another study [16] . A 139 study of 83 isolates of Veillonella (52 isolates of V. parvula) showed resistance to 140 penicillin in 59% and resistance to clindamycin in 7% of them. In the present study, no 141 resistance to metronidazole or imipenem was detected [17] . In a very recent study of 142 Veillonella isolates (n=17) in Greece [18], 29.4% were resistant to penicillin and 35.3% 143 to ampicillin, with a beta-lactamase production rate of 29.4%, and 17.6% were resistant 144 to piperacillin-tazobactam, 11.8% to clindamycin, and 5.9% to moxifloxacin; no 145 resistance to metronidazole was observed. However, a study in Taiwan found that 20% 146 of Veillonella spp. isolates were resistant to metronidazole [19] . In the present case, the 147 strain was resistant to penicillin, piperacillin-tazobactam, and metronidazole. 148 Taken together, the above findings indicate an increased resistance of Veillonella spp. to been reported in different countries. Susceptibility testing of these strains is essential to 152 develop the optimal therapeutic strategy against these infections. 153 In conclusion, this is the second report of V. dispar isolated in pure culture and 154 confirmed by 16S rRNA gene sequencing as a cause of bacteremia, indicating that this 155 pathogen can be responsible for severe infections. This case report and recent 156 observations of antimicrobial susceptibility among Veillonella spp. highlight an 157 increased resistance to various antimicrobials and emphasize the need for antimicrobial 158 susceptibility testing of all isolates. 159 Recoverey of Veillonella from saliva Targeted profiling of oral 190 bacteria in human saliva and in vitro biofilms with quantitative real-time PCR The veillonellae: gram-negative cocci 193 with a unique physiology Evaluation of general 16S ribosomal RNA gene PCR primers for classical 196 and next-generation sequencing-based diversity studies European Committee on antimicrobial susceptibility testing. Breakpoint tables for 199 interpretation of MICs and zone diameters Performance Standards for 201 antimicrobial susceptibility testing Veillonella parvula bacteremia without an underlying 204 source Two fatal cases of Veillonella 206 bacteremia Prosthetic joint infection due to Veillonella dispar Endocarditis caused by Veillonella dispar Comparative in vitro activity of new beta-lactam 225 antibiotics against anaerobic bacteria Evaluation of the routine 228 antimicrobial susceptibility testing results of clinically significant anaerobic bacteria in 229 a Slovenian tertiary care hospital in 2015 Surveillance of 231 antimicrobial resistance in recent clinical isolates of Gram-negative anaerobic bacteria 232 in a Greek University Hospital High incidence of 234 cefoxitin and clindamycin resistance among anaerobes in Taiwan